Ratings by Lucid Capital Markets (Dev Prasad)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/24/2026 | Turn Therapeutics | TTRX | New Coverage | Buy (N/A) |
13.51 (10.28) |
-23.91% | Details | |
| 9/14/2026 | Faeth Therapeutics | FTH | New Coverage | Buy (N/A) |
37.44 (17.08) |
-54.38% | Details | |
| 9/8/2026 | Adlai Nortye Ltd. | ANL | New Coverage | Buy (N/A) |
15.01 (10.58) |
-29.51% | Details | |
| 8/20/2026 | Eloxx Pharma | ELOX | New Coverage | Buy (N/A) |
18.16 (12.80) |
-29.52% | Details | |
| 7/27/2026 | Polaryx Therapeutics | PLYX | New Coverage | Buy (N/A) |
2.05 (1.85) |
-9.76% | Details | |
| 5/4/2026 | Quoin Pharmaceuticals | QNRX | New Coverage | Buy (N/A) |
6.21 (4.02) |
-35.27% | Details | |
| 2/24/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Palatin Technologies | PTN | New Coverage | Buy (N/A) |
19.63 (5.11) |
-73.97% | Details | |
| 11/5/2025 | Verrica Pharmaceuticals | VRCA | New Coverage | Buy (N/A) |
3.28 (3.53) |
7.62% | Details | |
| 9/15/2025 | aTyr Pharma | ATYR | Downgrade | Neutral (Buy) |
6.03 (0.17) |
-97.18% | Details | |
| 8/25/2025 | Cue Biopharma | CUE | New Coverage | Buy (N/A) |
0.83 (18.66) |
2148.19% | Details | |
| 6/17/2025 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
0.94 (3.47) |
269.15% | Details | |
| 5/23/2025 | Edesa Biotech Inc. | EDSA | New Coverage | Buy (N/A) |
2.01 (2.77) |
37.81% | Details | |
| 3/18/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
27.50 (125.10) |
354.91% | Details | |
| 12/17/2024 | Avalo Therapeutics Inc. | AVTX | New Coverage | Buy (N/A) |
9.42 (6.93) |
-26.43% | Details | |
| 12/17/2024 | iBio, Inc. | IBIO | New Coverage | Buy (N/A) |
2.35 (0.72) |
-69.36% | Details | |
| 12/17/2024 | CalciMedica | CALC | New Coverage | Buy (N/A) |
2.81 (1.23) |
-56.23% | Details | |
| 11/19/2024 | Inflarx NV | IFRX | New Coverage | Buy (N/A) |
1.74 (1.56) |
-10.34% | Details | |
| 11/19/2024 | aTyr Pharma | ATYR | New Coverage | Buy (N/A) |
3.01 (6.03) |
100.33% | Details |
